. Author manuscript; available in PMC: 2010 Oct 1.

Published in final edited form as: Clin Cancer Res. 2008 Sep 15;14(18):5810–5818. doi: 10.1158/1078-0432.CCR-07-5202

Table 2.

Multivariate analysis of Bim immunoscore and DFS and OS

Variable (n = 361)	DFS		OS

	HR (95% CI)	P^*	HR (95% CI)	P^*
Bim immunoscore (elevated vs negative)	0.63 (0.42–0.94)	0.0298	0.65 (0.44–0.98)	0.0447
Histologic grade (3 and 4 vs 1 and 2)^†	1.28 (0.91–1.82)	0.1666	1.37 (0.98–1.93)	0.0701
TNM stage (III vs II)	2.63 (1.48–4.67)	0.0002	2.63 (1.52–4.58)	<0.0001
Treatment (effective vs control/ineffective)	0.77 (0.44–1.35)	0.3709	0.70 (0.40–1.22)	0.2163
Age (10-y increase)	1.07 (0.91–1.26)	0.3831	1.21 (1.02–1.43)	0.0211

Likelihood ratio P value also adjusted for adjuvant study.

^†

Grade 1 and 2 (well/moderate); grade 3 and 4 (poor/undifferentiated).